May 14, 2007 — Two renowned experts debated the role of PCI and coronary artery bypass grafting (CABG) for the treatment ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
May 14, 2007 — More than 25 leading heart advocacy groups have joined to form the Sudden Cardiac Arrest (SCA) Coalition ...
May 13, 2007
May 11, 2007 — Northwestern University in Chicago has published results of a one-year study of roughly 5,500 patients ...
May 10, 2007May 9 — Brookwood Pharmaceuticals, Inc. and Targeted Technology Ventures LLC have announced the creation of a ...
May 08, 2007May 8, 2007 - OBS Medical and Physio-Control Inc., a wholly-owned subsidiary of Medtronic Inc., announced they have ...
May 07, 2007
Feature | Mark Paquin
Examples of physicians’ declining use of drug-eluting stents are growing.
According to Dr. Louis Cannon, Cardiac & ...
May 07, 2007
Feature | Richard R. Rogoski
When it comes to treating patients suffering from heart failure, which is typically defined as a heart whose ...
May 07, 2007
Feature | Richard R. Rogoski
In the simplest of terms, a ventricular assist device (VAD) is a battery-operated mechanical pump that helps a weakened ...
May 07, 2007May 7, 2007 — Citing issues related to potentially suboptimal therapeutic dosing of paclitaxel, Conor Medsystems, LLC ...
May 06, 2007April 9, 2007 — MIV Therapeutics Inc. has announced that its recent bench test confirmed that merging Biosync Scientific ...
April 07, 2007April 9, 2007 — The drug used in Johnson & Johnson’s drug-eluting stent — produced by J&J-owned Cordis — does not ...
April 07, 2007The results of Boston Scientific's pivotal SPIRIT III clinical trial reaffirmed prior safety and efficacy data ...
March 27, 2007Boston Scientific Corp. announced two-year results from the TAXUS V In-Stent Restenosis (ISR) trial, demonstrating ...
March 25, 2007March 9, 2007 — New studies show that about 60 percent of drug-eluting stents are used in off-label indications in the U ...
March 08, 2007Feb. 7, 2007 — Abbott has announced its plan to launch the world's first drug-eluting stent clinical trial solely in ...
February 06, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now